未经证实:HER2低表达乳腺癌(BC)约占所有BC病例的45%-55%。目的探讨HER2-低表达患者与HER2-零BC患者的预后差异。
未经授权:对Pubmed的电子搜索,Embase,科克伦图书馆,和WebofScience数据库用于筛选研究,这些研究包括HER2-0和HER2低表达组之间的预后比较.共纳入14项研究,涉及52106名患者。
UNASSIGNED:我们的结果表明,在所有早期BC患者中,HER2低表达与OS的显着益处相关(HR,0.83;95%CI,0.78-0.88),激素受体阳性BC患者(HR,0.83;95%CI,0.77-0.89),和TNBC患者(HR,0.78;95%CI,0.70-0.87)。在所有患者中,HER2低表达与DFS的显着获益相关(HR,0.81;95%CI,0.71-0.93),激素受体阳性BC患者(HR,0.81;95%CI,0.72-0.90),但在TNBC患者中DFS没有发现显著差异(HR,0.87;95%CI,0.65-1.17)。在所有患者中,HER2低表达与RFS的显着获益相关(HR,0.90;95%CI,0.85-0.95),激素受体阳性BC患者(HR,0.90;95%CI,0.84-0.96),但TNBC患者的RFS无显著差异(HR,0.80;95%CI,0.55-1.16)。
未经证实:在早期BC患者中,HER2低表达BC患者在总体人群中有较好的OS,激素受体阳性和TNBC亚组。此外,在总体人群和激素受体阳性亚组均观察到有利的DFS和RFS.
UNASSIGNED:https://www。crd.约克。AC.英国/PROSPERO/,标识符(CRD42022349458)。
UNASSIGNED: HER2-low expression breast cancer (BC) accounts for approximately 45%-55% of all BC cases. The purpose of this study was to investigate the prognostic difference between patients with HER2-low expression and HER2-zero BC.
UNASSIGNED: An electronic search of Pubmed, Embase, Cochrane Library, and Web of Science databases was performed to screen studies that included prognostic comparisons between HER2-zero and HER2-low expression groups. A total of 14 studies involving 52106 patients were included.
UNASSIGNED: Our results indicated that HER2-low expression was associated with a significant benefit in OS among all patients with early BC (HR, 0.83; 95% CI, 0.78-0.88), patients with hormone-receptor positive BC (HR, 0.83; 95% CI, 0.77-0.89), and patients with TNBC (HR, 0.78; 95% CI, 0.70-0.87). HER2-low expression was associated with a significant benefit in DFS among all patients (HR, 0.81; 95% CI, 0.71-0.93), patients with hormone receptor-positive BC (HR, 0.81; 95% CI, 0.72-0.90), but no significant difference in DFS was found in patients with TNBC (HR, 0.87; 95% CI, 0.65-1.17). HER2-low expression was associated with a significant benefit in RFS among all patients (HR, 0.90; 95% CI, 0.85-0.95), patients with hormone receptor-positive BC (HR, 0.90; 95% CI, 0.84-0.96), but no significant difference in RFS was found in patients with TNBC (HR, 0.80; 95% CI, 0.55-1.16).
UNASSIGNED: Among patients with early-stage BC, patients with HER2-low expression BC had better OS in the overall population, hormone receptor-positive and TNBC subgroups. Besides, favorable DFS and RFS were observed in both the overall population and hormone receptor-positive subgroup.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier (CRD 42022349458).